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Abstract
Background: Peristomal skin complications (PSCs) are the most common post-operative complications following creation of
a stoma. Living with a stoma is a challenge, not only for the patient and their carers, but also for society as a whole. Due to
methodological problems of PSC assessment, the associated health-economic burden of medium to longterm
complications has been poorly described.
Aim: The aim of the present study was to create a model to estimate treatment costs of PSCs using the standardized
assessment Ostomy Skin Tool as a reference. The resultant model was applied to a real-life global data set of stoma patients
(n=3017) to determine the prevalence and financial burden of PSCs.
Methods: Eleven experienced stoma care nurses were interviewed to get a global understanding of a treatment algorithm
that formed the basis of the cost analysis. The estimated costs were based on a seven week treatment period. PSC costs
were estimated for five underlying diagnostic categories and three levels of severity. The estimated treatment costs of
severe cases of PSCs were increased 2–5 fold for the different diagnostic categories of PSCs compared with mild cases.
French unit costs were applied to the global data set.
Results: The estimated total average cost for a seven week treatment period (including appliances and accessories) was
263J for those with PSCs (n=1742) compared to 215J for those without PSCs (n=1172). A co-variance analysis showed
that leakage level had a significant impact on PSC cost from ‘rarely/never’ to ‘always/often’ p,0.00001 and from ‘rarely/
never’ to ‘sometimes’ p=0.0115.
Conclusion: PSCs are common and troublesome and the consequences are substantial, both for the patient and from a
health economic viewpoint. PSCs should be diagnosed and treated at an early stage to prevent long term, debilitating and
expensive complications.
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Introduction
Creation of a stoma is a commonly performed and crucial
component of abdominal and general surgical practice. The
consequences for the patient can however be both complex and
life threatening [1]. Stoma complications occur with a high
frequency in spite of careful pre-operative planning, continuously
improving surgical technique and extensive surgical experience
[2]. It has been suggested that the complication rate appears to
have in fact remained the same for the last 50 years [3], despite
major advances in other aspects of medical and surgical care over
the same period. Stoma complications include necrosis, leakage,
granuloma formation, retraction, stenosis, prolapsed and para-
stomal hernia, and peristomal skin diseases [4]. While considerable
attention has been focused on the surgical complications in the
published literature, the consequences of peristomal skin compli-
cations (PSCs) have attracted less notice. PSCs are a constant
challenge for a great majority of individuals with a stoma. It is the
most common post-operative complication following creation of a
stoma. Various studies have reported a PSC rate ranging from 18–
60% [5–8] and a recent study reported that peristomal skin
problems account for about 40% of all visits to stoma care nurses
[9], suggesting that these problems play a greater role in the life of
people with stomas than generally acknowledged [10]. The risk is
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five years after operation [11] where a considerable reduction in
stoma diameter and height is generally the norm – hence requiring
adjustment of the appliance to minimize the risk of leakage and
PSCs.
There are several challenges in the assessment of PSCs, one
being to define the exact prevalence. The wide variation in
reporting the complications may be due to the less than systematic
assessment of the peristomal skin by different groups of health care
professionals who seldom communicate on aspects of PSCs. In
2008 Martins et al developed the Ostomy Skin Tool (OST) using a
simple and standardized approach for assessing peristomal skin
[12]. The intention was to improve patient monitoring and
optimize communication between health care professionals.
Currently, the OST is a widely used and accepted tool translated
into several languages. In Japan, this instrument has been
implemented as a national standard tool. Recently the tool was
validated and shown to be reliable [13,14].
Another challenge is to objectively assess the impact of PSCs.
One method of doing this could be to assess cost, either in terms of
utilities such as time [15] or actual monetary cost. Therefore the
aim of the present study was to create a model for cost assessment
of PSCs using the OST as a reference. These costs are important
to know for surgeons creating a stoma and for other stoma care
professionals as the quality of stoma creation, function, and stoma
care has a life-long direct impact on costs for the patients and
health care systems at a level never previously defined in a similar
approach. Finally the model was applied on a large real-life data
set from people with ostomies to assess the prevalence and
financial burden of PSCs.
Materials and Methods
Initially a literature search was performed to find published
relevant costs, cost estimations or health economic models on
PSCs, however no relevant data were identified. Hereafter it was
decided to create a model for cost estimations of PSCs.
Model design for cost estimation of PSCs
The structure of the model (Figure 1) was based on contribu-
tions from three stoma expert panels using the validated OST as
reference for determination of diagnosis categorization, severity
and care of PSCs. A seven week treatment period was determined
based on previous results from a recent study suggesting that
clinically significant improvement of PSCs can be expected during
a 6–8 week treatment period [7].
The Ostomy Skin Tool (OST)
The OST is a standardized assessment tool developed with the
aim to help health care professionals in evaluating and monitoring
the condition of peristomal skin reliably and accurately [12–14].
The OST generates an objective score based on clinical
observation of three domains: discoloration (D), erosion/ulcera-
tion (E), and tissue overgrowth (T). The three domains are scored
according to the extent of the involved peristomal area and the
severity of change in the skin. The combined score, or DET score,
is in the range from 0–15 where 0 represents normal skin and 15
the worst combination of severity and extent. The OST also
contains a full description of clinical signs for five diagnostic
categories of PSCs and a care guide for each of the categor-
ies..Contact dermatitis and allergic dermatitis are two subcatego-
ries of an overall ‘chemical irritation’ category and the last three
diagnostic categories are: mechanical trauma, disease related, and
infection related. A simplified use of the DET score has been
suggested [14] introducing three levels of severity ‘mild’ (DET,4),
‘moderate’ (DET$4,7), and ‘severe’ (DET$7).
Consensus of appropriate PSC treatment (Step 1)
Best local practice varies from country-to-country and site-to-
site. To develop an appropriate global understanding of a
treatment algorithm to be used in a cost analysis, 11 highly skilled
stoma care nurses from 9 countries were identified for interviews
based on their daily practice with PSCs and their experience with
the OST. The stoma care nurses were informed on the purpose of
the study by e-mail and acceptance to participate were confirmed
by e-mail. The nurses were interviewed face-to-face expressly for
this study and informed consents were re-obtained verbally ahead
of the interviews. The verbal consent was transcribed to interview
notes. Before the interviews the stoma care nurses were introduced
and trained in the simplified DET scale of 3 severity categories
‘mild’, ‘moderate’, and ‘severe’ which together with the OST care
guide were used as a common framework in the interviews. The
collection of interviews and analysis hereof were handled
anonymously.
The stoma care nurses’ recommendations for appropriate
treatment for each case of ‘irritant contact dermatitis’, ‘allergic
dermatitis’, ’mechanical trauma’, ‘disease related’ or ‘infection
related’ for all three levels of severity (mild, moderate and severe)
were recorded (see example Table 1). Health care spending was
captured for health care visits, changes in type or use of
appliances, medication, and surgery. The same interview questions
were given to a dermatologist with special expertise in stoma care
and the compilation of all interviews formed a global understand-
ing of average treatment for every diagnostic category and severity
level of PSC (15 subcategories in total). Complete treatment
algorithms are available in Table S1.
Assignment of cost for health care spending (step 2)
France was chosen as the country of reference because the cost
of appliances is independent of the manufacturer. A unit cost was
assigned for each treatment item to determine the cost induced by
each subcategory of PSC. In France e.g., a typical treatment with
topical corticosteroid costs 2.57J and a stoma care nurse visit is
estimated to cost 15J. The French unit costs for all products
applied in this model can be found in Table S2.
The DialogueStudy
To determine the distribution of treatment costs for the different
diagnostic categories of PSCs and level of severity, the model was
applied on data from the DialogueStudy (DS). The DS is the
largest study ever undertaken in stoma care practice with more
than 3000 people with a stoma enrolled from 18 countries [16].
The results from the DS provided a wealth of data on PSCs
combined with leakage, ostomy appliance performance and
quality of life assessed with the validated Stoma-Quality of Life
(QoL) questionnaire [17]. In the DS, the participants’ PSCs were
assessed using the OST. Baseline data of gender distribution, type
of stoma (colo-, ileo- or urostomy), mean age and mean time since
surgery and presence of PSCs are listed in Table 2 and Table 3. In
the model patients with multiple causes of PSCs or cause recorded
as ‘other’ were assigned an imputed cost equal to the weighted
average cost for a patient with known causes of PSCs with the
same level of severity.
Sensitivity analysis (Tornado diagram)
Treatment cost estimation of PSCs was based on typical
treatment patterns and did not rely on observed health care
Cost of Peristomal Skin Complications
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with respect to the unit cost established by this method, a
sensitivity analysis was conducted. Each of the 15 categories listed
in Table 4 were varied by 620% and the PSC cost estimates were
re-established for baseline population in the DS, freezing the cost
for the 14 other categories. The resulting 2615 estimates are
depicted in a Tornado diagram Figure 2. The Tornado diagram
illustrates which of the 15 estimated category cost has the largest
impact on the overall PSC cost estimate.
Statistical methods
The baseline PSC treatment costs are analyzed using a linear
normal based analysis of covariance (multivariate analysis). PSC
treatment costs are furthermore analyzed using a logarithmic
transformation. Transforming estimates back, relative differences
are obtained instead of absolute differences.
The covariates considered were:
N Type of ostomy
N One or two piece appliance
N Convex or non-convex baseplate
N Frequency of clinic visit to SCN or doctor
N The baseline leakage level (on a 3-level scale)
N Time span since stoma creation
N Reason for the stoma creation
N Permanency of stoma
N Age and gender of the patient
N Country and center treating the patient
The same sets of covariates were used for total and PSC cost
analysis.
Ethic statement
No ethic approval was obtained for the study as the study design
is based on treatment algorithms, cost estimations and analysis of
already published data from the Dialogue Study.
The stoma care nurses were informed on the purpose of the
study by e-mail and acceptance to participate were confirmed by
e-mail. The nurses were interviewed face-to-face expressly for this
study and informed consents were re-obtained verbally ahead of
the interviews. The verbal consent was transcribed to interview
notes.
Results
The model created was used to estimate the treatment costs for
managing an average case of PSC for all levels of severity and
Figure 1. Model design for cost estimation of PSC.
doi:10.1371/journal.pone.0037813.g001
Table 1. Example of recommended management of
‘moderate’ irritant contact dermatitis.*
Moderate irritant contact dermatitis
Freq. (%) Health Care Intervention
100 SCN consultation
51 2
nd SCN consultation
15 3
rd SCN consultation
6 Topical corticosteroid therapy
*Based on interviews of expert stoma care nurse (SCN).
doi:10.1371/journal.pone.0037813.t001
Table 2. Patient characteristics DS.
Participants (N) %
Gender Males 1474 49
Females 1541 51
Type of stoma Colostomy 2015 67
Ileostomy 954 31
Urostomy* 46 2
PSC Yes 1742 60
No 1175 40
*People with urostomies were not enrolled in all countries. DS=Dialogue
Study. PSC=Peristomal Skin Complication.
doi:10.1371/journal.pone.0037813.t002
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results are listed in Table 4 and are presented in euros based on
French unit costs in 2011.
The treatment cost of severe cases of PSC increased 2–5 fold for
the different categories of PSCs compared with mild cases of PSCs.
The change in cost from mild to moderate cases showed an
additional cost ranging from 4–47J with ‘disease related’ PSCs at
the highest end.
The model was applied on the real-life baseline data from the
DS. The treatment cost of a PSC was calculated for each patient
where treatment of a patient with normal skin was assigned a
treatment cost of zero. Based on the assumption that the numbers
of appliance (baseplate and pouches) changes were the same for
patients with and without PSCs, the total average cost for a 7 week
treatment period (including appliances and accessories) was 263J
(n=1742) for those with PSCs and 215J (n=1172) for those
without PSC. Forty-three percent suffered from a ‘mild’ PSC, 42%
had a ‘moderate’ PSC and 15% percent suffered from a severe
PSC (Figure 3A). The treatment cost for the severe group was 6.1
fold higher compared with ‘mild’ cases and 4.5 fold higher
compared with moderate cases (Figure 3B). The distribution of
underlying causes of PSCs are shown in Figure 4A and the
estimated treatment cost in Figure 4B. ‘Allergic dermatitis’,
‘disease related’ and ‘infection related’ had the highest estimated
treatment cost (70.3J, 102.0J and 60.4J respectively).
In the DS, 58% of the participants had their stoma created as
part of their treatment for cancer. The treatment cost of PSCs
were in the same range [24–35.4J] independent of the underlying
reason for stoma creation. DS participants with PSCs had an
ileostomy or colostomy in 35% and 65% of the cases respectively.
The average treatment cost for a patient with an ileostomy was
32.1J and 24.0J for a patient with a colostomy (Table 5).
Twenty-four percent of the participants in the DS experienced
‘always/often leakage’ and had the highest estimated cost (45.6J)
compared with the group who ‘sometimes’ experienced leakage
(28.3J) or ‘rarely/never’ (16.7J) (Figure 5A and B).
A co-variance analysis was performed to test for factors
influencing the treatment cost of PSCs at baseline. Of the different
variables tested leakage had a high statistically significant impact
on the treatment cost of PSCs. From ‘rarely/never’ to ‘always/
often’ there was a statistically significant impact on PSC treatment
cost (p,0.00001) with a difference in an average cost of 29J and
from ‘sometimes’ to ‘rarely/never’, p=0.0115 with an estimated
difference in average cost of 11J. Furthermore, a borderline
significant impact (p=0.0422) was seen for ‘year of age at
baseline’.
Table 3. Patient characteristics DS.
Mean ± SD
Mean age (years) 63.2614.3
Time since surgery (years) 5.967.9
doi:10.1371/journal.pone.0037813.t003
Figure 2. Sensitivity analysis of ±20% change in PSC cost presented in Tornado diagram.
doi:10.1371/journal.pone.0037813.g002
Table 4. Cost of managing a case of PSC by cause and
severity.*
Diagnostic category Mild Moderate Severe
Irritant contact dermatitis 20.86 24.89 152.19
Allergic reaction 46.92 68.02 106.23
Mechanical trauma 18.63 23.30 113.93
Disease related 40.45 87.91 195.82
Infection 35.39 49.24 167.69
*Mild: DET score,4; Moderate: DET Score,7; Severe: DET score$7.
DET=Discoloration, Erosion/Ulceration, Tissue-overgrowth. PSC=Peristomal
Skin Complication. Cost estimations are based on French unit cost in 2011
(Euro).
doi:10.1371/journal.pone.0037813.t004
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15 categories of PSCs was performed to assess the robustness of the
model and the estimated cost related to PSCs. The outcome of the
analysis is presented as a Tornado diagram in Figure 2. The results
show that changes in the cost of a severe irritant contact dermatitis
has the largest impact on the cost of PSCs. However the PSC cost
estimate is robust to changes in the 15 subcategories; for instance
the PSC cost changed 0.3% for a 1% change in the cost of a severe
irritant contact dermatitis (at the top of the Tornado diagram), and
less with any of the other 14 subcategories.
Discussion
Surgical formation of a stoma is a significant clinical procedure
in numerous ways, with stoma patients facing emotional, physical
and social challenges. Stoma related complications occur fre-
quently creating specific care problems and may have a major
impact on the outcome in terms of patients’ coping with their new
life style. Living with a stoma is a challenge not only for the patient
and their relatives and carers but also for society as a whole. In the
long term it may be associated with increased absence from work
due to illness, or to the need for early retirement, both significant
health-economic burdens. The most common post-operative
complication is PSCs [4]. The degree of peristomal skin irritation
may range from that of a mild peristomal dermatitis to full-
thickness skin necrosis and ulceration. A mild skin disorder if not
taken seriously can rapidly progress into a more severe condition
requiring medical action [6]. It is imperative that people with a
stoma regularly check the peristomal skin and seek professional
advice in a timely manner if deterioration in skin condition is
observed.
In the current climate of limited available resources it is
important to be aware of the most optimal use of resources. The
aim of the present study was to create a model for cost estimation
of PSCs. Interviews formed the basis for a model treatment
algorithm for ‘mild’, ‘moderate’, and ‘severe’ cases of PSCs in five
different underlying disease categories using the validated OST as
a common reference tool. Not surprisingly there was a general
Figure 3. Cost of PSC according to level of severity (DS). PSC: Peristomal Skin Complication. DS: Dialogue Study.
doi:10.1371/journal.pone.0037813.g003
Figure 4. Cost of PSC according to diagnostic categories (DS). *Other: Was assigned an imputed cost equal to the weighted average cost for
a patient with known cause of PSC with the same level of severity. PSC: Peristomal Skin Complication. DS: Dialogue Study.
doi:10.1371/journal.pone.0037813.g004
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comprehensive treatment and health care utilization than mild
cases of PSCs. Usually patients with mild PSCs only have slight
skin changes, involving a small area of the skin and requiring no
active treatment. Based on French unit costs treatment of a ‘mild’
PSC was estimated to add extra cost in the range of 19–40J per
patient for a seven week period. The main primary cost is for
consultation fees. For moderate PSC, definite skin changes are
seen, e.g. ulcers in the peristomal region and usually a larger area
is involved. Furthermore non-prescription treatment may be
required. The model based estimated extra cost for a moderate
PSCs was in the range of 23–88J per patient over ostomies
without PSCs. For severe PSCs immediate attention is often
needed e.g. systemic steroids or anti-bacterial treatment [18]. A
severe condition often involves the whole skin surface beneath the
appliance system and complicates the adhesion of the baseplate to
the skin. Therefore a severe PSC has a significantly higher
estimated added cost in the range of 106–196J per patient for a
seven week treatment period.
To determine the distribution of treatment cost for the different
diagnostic categories of PSCs and the level of severity, the created
model was applied on the real-life baseline data from the DS study
as it is a large and well described published study – the largest of its
kind including 3017 participants with a colostomy, ileostomy or
urostomy [16]. The results showed that the overall average cost for
an estimated seven week treatment period (incl. appliances and
accessories) was 263J per patient (n=1742) for those with PSCs
and 215J per patient for those without PSCs. This is an additional
cost of almost 50J for those with PSCs for a seven week treatment
period. France has approximately 114,000 people with ostomies
(according to survey conducted by the French association of stoma
care nurses (A.F.E.T.)). Given the prevalence of PSCs of 60% in
the Dialogue Study requiring PSC treatment, this represents 3.4
million euros of additional costs over seven weeks and 25.4 million
euros yearly in France, assuming that all patients with a stoma
have had adequate access to stoma care nursing. Fifteen percent of
the participants from the DS suffered from severe PSCs. The
treatment cost for this group was estimated to be 6.1 fold higher
compared with ‘mild’ cases and 4.5 fold higher compared with
‘moderate’ cases. It is also the case for pre-existing skin diseases
including atopic dermatitis and psoriasis that often become
aggravated on the peristomal skin and exacerbate the severity of
the complication and hereby the need for active treatment. The
estimated treatment costs for the underlying diseases in the DS
showed that ‘Allergic dermatitis’, ‘disease related’ and ‘infection
related’ had the highest costs (70.3J, 102.0J and 60.4J
respectively). People with stomas suffering from pre-existing skin
Table 5. Cost of PSC (euro).
N % Treatment cost mean (J) Total treatment cost
1 mean (J)
Type of stoma Colostomy 1125 65 24.0 244.2
Ileostomy 617 35 32.1 241.6
Reason for stoma Cancer 949 55 24.2 242.4
Ulcerative colitis 211 12 26.9 236.2
Crohns disease 170 10 34.1 246.3
Diverticulitis 123 7 35.4 254.8
Other 268 16 27.8 246.5
1Including appliances and accessories. PSC=Peristomal Skin Complication.
doi:10.1371/journal.pone.0037813.t005
Figure 5. Cost of PSC according to leakage level (DS). PSC: Peristomal Skin Complication. DS: Dialogue Study.
doi:10.1371/journal.pone.0037813.g005
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more severe PSCs, subsequently reducing costs.
Unfortunately for many patients, PSCs may result in a vicious
circle where the skin problem causes failure of the adhesive, which
in turn gives rise to leakage and again can lead to more recalcitrant
skin problems. Leakage is particularly problematic for patients
with an ileostomy, because the condition of their skin is likely to
deteriorate rapidly following leakage [18]. The absence of colonic
function in patients with an ileostomy leads to more frequent stool,
thus resulting in a greater risk of skin irritation compared with
individuals with a colostomy [19]. Unsurprisingly, peristomal
leakage, PSCs and overall QoL are interconnected [6,20] and the
global results from the DS confirmed that leakage is a critical
factor in the development of PSC [21]. Testing the influence of
several co-variables on PSC costs, leakage turned out to have the
highest impact in the present study. From a leakage perspective of
‘rarely/never’ to ‘always/often’ there was a statistical significant
impact on PSC cost (p,0.00001) and from ‘sometimes’ to ‘rarely/
never’, p=0.0115.
The management of leakage, the involvement and support of a
SCN and the use of an appropriate appliance and accessories
could potentially save money over the long term. In addition the
frequency and severity of PSCs has a major impact on a patient’s
quality of life and overall daily living. A key aspect in optimal
stomal function relates to stomal construction. Two recent papers
have reported on the importance of high quality stoma construc-
tion, including adequate stoma length to minimize leakage under
the adhesive and consequently the possibility of PSC [3,4].
The presented model gives an estimation of the cost associated
with different forms of PSCs. A similar approach has not been
published to date involving experts in the field from different
professional perspectives. The sensitivity analysis of the model
showed that the PSC cost estimate is robust to changes in all 15
diagnostic subcategories.
Limitations of the study
The model outlined, and the estimated costs, however has a
number of limitations. All treatment estimates are based on a
global understanding from expert experiences applied to average
PSC cases and not on real-life observations. If local treatment
differs significantly from the global understanding it should be
considered to adjust the treatment algorithm accordingly. The
estimated costs are for a seven week treatment nevertheless the
analysis does not address the outcome of the PSC after this period.
In France, only four out of the 12 accessories recorded in the DS
are paid by the health care system and therefore only these are
incorporated in the total cost estimations. As all costs are based on
French unit cost a re-estimation should be considered if local unit
cost deviates significantly from French costs.
Several of these limitations could be addressed by a future real-
life study following stoma patients and their PSCs over a longer
period e.g. six months to explore the precise effect of treatment,
extent of recurrent PSC and the appropriate resources needed.
PSCs are a common post-operative complication. It affects the
patient physically and psychologically, ultimately prolonging
rehabilitation and adaptation to the stoma. Furthermore PSCs
significantly increase the cost both for society but also for the
individual living with a stoma. Ideally PSCs should be prevented
and awareness of the data presented here is important to disclose
to surgeons creating a stoma and to other stoma care professionals
(e.g dermatologists) as the quality of stoma construction and
management may have a life-long direct impact for the patient’s
well being and major financial implications for the health care
system.
Conclusion
PSCs are common and both frequency and severity are under-
recognized and under-reported. A key causative factor is
undoubtedly peristomal leakage and individuals with an ileostomy
are most at risk from a combination of the higher output and
irritant nature of the effluent as compared with those people with a
colostomy.
The consequences of PSCs are substantial, both from the
patient and the health economy viewpoint. The extent of the
problem warrants a major focus on methods to minimize the risk,
detect PSCs at an early stage and institute optimal treatment to
prevent the long-term, debilitating and expensive complications.
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